134 related articles for article (PubMed ID: 31104736)
1. Multivariable and Structural Uncertainty Analyses for Cost-Effectiveness Estimates: Back to the Future.
Mauskopf J
Value Health; 2019 May; 22(5):570-574. PubMed ID: 31104736
[TBL] [Abstract][Full Text] [Related]
2. Representing uncertainty: the role of cost-effectiveness acceptability curves.
Fenwick E; Claxton K; Sculpher M
Health Econ; 2001 Dec; 10(8):779-87. PubMed ID: 11747057
[TBL] [Abstract][Full Text] [Related]
3. Severity-Adjusted Probability of Being Cost Effective.
Versteegh MM; Ramos IC; Buyukkaramikli NC; Ansaripour A; Reckers-Droog VT; Brouwer WBF
Pharmacoeconomics; 2019 Sep; 37(9):1155-1163. PubMed ID: 31134467
[TBL] [Abstract][Full Text] [Related]
4. When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidence.
Siebert U; Rochau U; Claxton K
Z Evid Fortbild Qual Gesundhwes; 2013; 107(9-10):575-84. PubMed ID: 24315327
[TBL] [Abstract][Full Text] [Related]
5. Subgroup analyses in cost-effectiveness analyses to support health technology assessments.
Fletcher C; Chuang-Stein C; Paget MA; Reid C; Hawkins N
Pharm Stat; 2014; 13(4):265-74. PubMed ID: 24931490
[TBL] [Abstract][Full Text] [Related]
6. Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods.
O'Brien BJ; Briggs AH
Stat Methods Med Res; 2002 Dec; 11(6):455-68. PubMed ID: 12516984
[TBL] [Abstract][Full Text] [Related]
7. Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.
Ghabri S; Hamers FF; Josselin JM
Pharmacoeconomics; 2016 Jun; 34(6):617-24. PubMed ID: 26829942
[TBL] [Abstract][Full Text] [Related]
8. "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.
Alarid-Escudero F; Enns EA; Kuntz KM; Michaud TL; Jalal H
Value Health; 2019 May; 22(5):611-618. PubMed ID: 31104743
[TBL] [Abstract][Full Text] [Related]
9. A comparison of two methods for expert elicitation in health technology assessments.
Grigore B; Peters J; Hyde C; Stein K
BMC Med Res Methodol; 2016 Jul; 16():85. PubMed ID: 27456844
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity analysis for handling uncertainty in an economic evaluation.
Limwattananon S
J Med Assoc Thai; 2014 May; 97 Suppl 5():S59-64. PubMed ID: 24964700
[TBL] [Abstract][Full Text] [Related]
11. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
12. The use of probabilistic decision models in technology assessment : the case of total hip replacement.
Briggs A; Sculpher M; Dawson J; Fitzpatrick R; Murray D; Malchau H
Appl Health Econ Health Policy; 2004; 3(2):79-89. PubMed ID: 15702945
[TBL] [Abstract][Full Text] [Related]
13. Complementing the net benefit approach: a new framework for Bayesian cost-effectiveness analysis.
Hernández MA; Vázquez-Polo FJ; González-Torre FJ; Bas EM
Int J Technol Assess Health Care; 2009 Oct; 25(4):537-45. PubMed ID: 19845984
[TBL] [Abstract][Full Text] [Related]
14. Toward a Broader Concept of Value: Identifying and Defining Elements for an Expanded Cost-Effectiveness Analysis.
Garrison LP; Kamal-Bahl S; Towse A
Value Health; 2017 Feb; 20(2):213-216. PubMed ID: 28237197
[TBL] [Abstract][Full Text] [Related]
15. The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports.
Taylor RS; Elston J
Health Technol Assess; 2009 Jan; 13(8):iii, ix-xi, 1-50. PubMed ID: 19203465
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity analysis in cost-effectiveness studies: from guidelines to practice.
Jain R; Grabner M; Onukwugha E
Pharmacoeconomics; 2011 Apr; 29(4):297-314. PubMed ID: 21395350
[TBL] [Abstract][Full Text] [Related]
17. How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.
Bojke L; Manca A; Asaria M; Mahon R; Ren S; Palmer S
Pharmacoeconomics; 2017 Aug; 35(8):767-776. PubMed ID: 28470594
[TBL] [Abstract][Full Text] [Related]
18. Incorporating option values into the economic evaluation of health care technologies.
Palmer S; Smith PC
J Health Econ; 2000 Sep; 19(5):755-66. PubMed ID: 11184803
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
